CONTENTS 目錄 In the first half of 2025, the Group continued to be committed to the development of the water resources industry and the beer industry in Tibet, striving to enhance the user experience and optimize channel expansion, so as to enable Tibet's distinctive and premium products to reach more consumers and potential consumers. | FINANCIAL HIGHLIGHTS | 2 | | --- | --- | | 財務摘要 | | | MANAGEMENT DISCUSSION AND ANALYSIS | 3 | | 管理層討論及分析 | | | CORPORATE GOVERNANCE PRACTICES | 13 | | 公司管治常規 | | | FINANCIAL ...

大唐西市絲路投資控股有限公司 DTXS SILK ROAD INVESTMENT HOLDINGS COMPANY LIMITED (於百慕達註冊成立之有限公司) (股份代號: 620) (Incorporated in Bermuda with limited liability) (Stock Code: 620) 大唐西市絲路投資控股有限公司 DTXS SILK ROAD INVESTMENT HOLDINGS COMPANY LIMITED DTXS SIL K R OAD INVEST MENT HOL DINGS C O MPANY LI MITE D 大 唐 西 市 絲 路 投 資 控 股 有 限 公 司 Interim Report 2025 中 期 報 告 目錄 | 公司資料 | 2 | | --- | --- | | 管理層討論及分析 | 3 | | 其他資料 | 7 | | 簡明綜合損益及其他全面收益表 | 14 | | 簡明綜合財務狀況表 | 16 | | 簡明綜合權益變動表 | 18 | | 簡明綜合現金流量表 | 19 | | 簡明中期財務資料附註 | 20 | 公司資料 董事會 ...

1 擎華控股集團有限公司 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM之定位，乃為較於聯交所上市之其他公司帶有更高投資風險之中小型公司提供一個上 市之市場。有意投資之人士應了解投資於該等公司之潛在風險，並應經過審慎周詳之考慮 後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受 較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本報告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容產生或 因倚賴該等內容引致之任何損失承擔任何責任。 本報告乃遵照香港聯合交易所有限公司GEM證券上市規則之規定提供有關擎華控股集團有 限公司之資料。擎華控股集團有限公司各董事願就本報告共同及個別承擔全部責任，並經作 出一切合理查詢後確認，就彼等所深知及確信，本報告所載之資料在各重大方面均屬準確及 完整，且無誤導或欺詐成份；及本報告並無遺漏其他事實致使本報告所載任何陳述產生誤 導。 二零二五年中期報告 2 公司資料 執行董事 唐才智先生 （主席） 鍾楚霖先 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of HK$500 million for the interim period, representing a 25% year-over-year growth[1]. - For the six months ended June 30, 2025, the company's revenue increased by 1.3% to RMB 209.2 million from RMB 206.4 million for the same period in 2024[35]. - The total comprehensive loss for the period was RMB 92.6 million, a decrease from RMB 114.1 million in the same period of 2024[136]. - Adjusted total comprehensive loss for the period was RMB 72.151 million for the six months ended June 30, 2025, compared to RMB 97.659 million for the same period in 2024[51]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost optimization strategies[1]. - Gross profit increased by 2.1% to RMB 192.9 million from RMB 188.9 million for the same period in 2024, with a gross profit margin of 92.2% compared to 91.5% in 2024[37]. User Growth and Market Expansion - User data showed a 30% increase in active users, reaching 1.2 million by the end of the reporting period[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share within the next two years[1]. - The company is focusing on accelerating product development and commercialization processes to enhance operational efficiency and bring forward novel medicines[198]. - The company aims to strategically collaborate with partners to expand into emerging markets for the development and commercialization of 恩維達®[200]. Research and Development - Research and development efforts focused on the new PD-L1 inhibitor, ENWEIDA, which is expected to enter clinical trials in Q3 2025[1]. - The company is involved in the research and development of PD-1 and PD-L1 related therapies, targeting non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC)[9]. - The company has advanced a proprietary 177Lu-labeled PSMA-targeted RDC, which is now in the investigator-initiated trial (IIT) stage[29]. - The ongoing development of Envafolimab includes multiple clinical trials demonstrating its efficacy and safety across various cancer types[26][27]. - The company has established a comprehensive nucleic acid drug development system, including drug design, preparation, and preclinical research, with a focus on tumor neoantigen vaccines and the development of the 3D-PreciseAg antigen prediction system[115]. Product Development and Commercialization - The company has commercialized Envafolimab, which is now sold in over 3,000 hospitals and 760+ pharmacies across 30 provinces in China[133]. - Envafolimab achieved sales revenue of RMB 209.2 million in China for the first half of 2025, contributing to a total sales of approximately RMB 1.9 billion[58]. - The company is developing a new mRNA therapeutic cancer vaccine, 3D124, which targets multiple tumor-specific antigens and has shown strong anti-tumor effects in pre-clinical studies[95]. - The production capacity expansion for Envafolimab Injection received official approval from the National Medical Products Administration (NMPA) in the first half of 2025, enhancing manufacturing capabilities to meet growing market demand[125]. Strategic Partnerships and Acquisitions - A strategic acquisition of a local biotech firm was announced, which is expected to enhance the company's product pipeline and capabilities[1]. - The company has initiated a partnership with a leading pharmaceutical company to co-develop new therapies, aiming for a launch by 2026[1]. - The company has established a licensing agreement with Glenmark and is actively pursuing overseas licensing opportunities for Envafolimab in additional countries and regions[62]. Financial Position and Cash Flow - Cash and bank balances as of June 30, 2025, were RMB 660.5 million, down from RMB 864.3 million as of December 31, 2024[34]. - The net cash used in operating activities for the six months ended June 30, 2025, was RMB 205.8 million, compared to RMB 179.7 million for the same period in 2024[170]. - The Group's total revenue increased by approximately 1.3% compared to the corresponding period in 2024, driven by improved market conditions and strong sales execution[58]. - Total current assets decreased by RMB 185.2 million to RMB 802.6 million as of June 30, 2025, from RMB 987.8 million as of December 31, 2024[165][167]. Corporate Governance and Structure - The company has undergone changes in its board of directors, with new appointments and resignations effective June 30, 2025[12]. - The principal bank for the company is Bank of Communications, indicating a stable banking relationship for financial operations[15]. - The company is registered in the Cayman Islands, with its corporate headquarters located in Qingdao, Shandong, PRC[15]. Employee and Operational Insights - The Group had 183 full-time employees as of June 30, 2025, with total employee benefits expenses of approximately RMB 63.4 million for the six months ended June 30, 2025[192]. - Employee recruitment is based on various factors, including work experience and educational background, with ongoing training programs provided to enhance skills and knowledge[197]. - The company is building differentiated commercial capabilities in mainland China and plans to expand these capabilities in the global market[199].

Financial Performance - For the six months ended June 30, 2025, revenue increased to RMB 382.26 million, up 37.5% from RMB 277.84 million in the same period of 2024[19]. - Gross profit for the same period was RMB 149.54 million, representing a 30.3% increase compared to RMB 114.77 million in 2024[19]. - Profit for the period reached RMB 10.26 million, a significant increase of 201.5% from RMB 3.40 million in the previous year[19]. - Earnings per share attributable to ordinary equity holders rose to RMB 3.16 cents, compared to RMB 1.07 cents in 2024, marking a 195.3% increase[19]. - Revenue increased by 37.6% from RMB 277.8 million for the six months ended June 30, 2024, to RMB 382.3 million for the six months ended June 30, 2025[55]. - Revenue from online reading platform services rose by 31.3% from RMB 105.8 million to RMB 139.0 million during the same period, driven by increased online reading advertising[56]. - Revenue from digital marketing services surged by 47.0% from RMB 156.6 million to RMB 230.3 million, attributed to higher advertising demand[57]. - Revenue from online games publishing services grew by 26.3% from RMB 5.3 million to RMB 6.7 million, due to enhanced marketing efforts for an overseas game[58]. - Revenue from other digital content services decreased by 37.8% from RMB 10.1 million to RMB 6.3 million, primarily due to a decline in music digital content revenue[61]. - Cost of sales increased by 42.7% from RMB 163.1 million to RMB 232.7 million, mainly due to rising costs in digital marketing services[62]. - Gross profit margin improved to 39.1% for the six months ended June 30, 2025, compared to 41.3% for the same period in 2024[76]. - Selling and distribution expenses rose by 53.9% to RMB 105.9 million for the six months ended June 30, 2025, accounting for 27.7% of total revenue[78]. - Administrative expenses decreased by 63.8% to RMB 8.4 million for the six months ended June 30, 2025, representing 2.2% of total revenue[79]. - Research and development expenses increased by 26.9% to RMB 22.3 million for the six months ended June 30, 2025, accounting for 5.8% of total revenue[80]. - Profit before tax for the six months ended June 30, 2025, was RMB 11.6 million, up from RMB 5.2 million in 2024[87]. - Net profit for the period increased to RMB 10.3 million for the six months ended June 30, 2025, compared to RMB 3.4 million for the same period in 2024, with a net profit margin of 2.7%[89]. Market and Industry Insights - The global generative AI in content creation market size was USD 14.81 billion in 2024, projected to grow at a CAGR of 32%, reaching USD 134.23 billion by 2032[21]. - The global generative AI content creation market is projected to reach USD 14.81 billion in 2024, with a compound annual growth rate (CAGR) of 32% expected until 2032[23]. - The global in-app purchase revenue from short drama applications reached nearly USD 700 million in Q1 2025, marking a nearly fourfold increase compared to the same period in 2024[30]. Research and Development - R&D expenses for AI-generated content and intelligent recommendation technology amounted to RMB 22.3 million in the first half of 2025[21]. - The company plans to strengthen its core advantages in AI-based recommendation technology and improve recommendation accuracy through algorithm upgrades in the second half of the year[39][42]. - The company will leverage the latest big model technology to build a multi-dimensional content understanding system, enhancing the accuracy and efficiency of its AI engine[40][43]. - The company aims to promote the commercial application of AI technology across various fields, including digital marketing and content generation, to improve marketing conversion efficiency[44][45]. - The company has invested in a series of R&D projects focused on improving the Easou Recommendation Engine, with a total of HK$6.1 million allocated, of which HK$2.9 million has been utilized[180]. Strategic Initiatives - The Group's proprietary Easou Recommendation Engine is continuously upgraded and applied across various business scenarios, enhancing its competitive advantage in the AI sector[6]. - The Group is actively exploring the integration of AI-based recommendation technology with blockchain technology in the RWA sector[7]. - Easou Technology signed a 10-year framework cooperation agreement with a Hong Kong technology company to jointly develop RWA products and other digital asset projects[33]. - The company has established a joint venture with Acceleronet HPC Limited and plans to complete a strategic investment in Lightnet Pte. Ltd. to advance its RWA and Web3.0 initiatives[51][52]. - The strategic partnerships will enable the company to leverage resource advantages and promote the construction of an on-chain rights confirmation and value conversion system for digital assets[52]. User Engagement and Growth - As of June 30, 2025, the cumulative registered users of Easou products reached 47 million, with an average monthly active user count of 25 million[26]. - In the first half of 2025, Easou Technology achieved revenue of RMB 230.3 million in digital marketing services, representing a year-on-year increase of 47.0%[25]. - Easou Technology is actively developing localized and customized short dramas based on overseas user preferences to enhance its globalization strategy[30]. - The company will focus on short drama content as a core entry point for global market expansion, targeting mature markets in Europe and America initially[46][49]. Financial Position and Assets - Total assets increased by 17.2% to RMB 798.2 million as of June 30, 2025, while total liabilities decreased by 27.2% to RMB 171.1 million[95]. - Net current assets rose by 55.6% to RMB 534.5 million as of June 30, 2025, driven by an increase in current assets and a decrease in current liabilities[96]. - Cash and cash equivalents rose by 60.6% from RMB 160.8 million as of December 31, 2024, to RMB 258.4 million as of June 30, 2025, primarily due to proceeds from share placement[122]. - Interest-bearing bank and other borrowings decreased by 31.5% from RMB 193.1 million as of December 31, 2024, to RMB 132.2 million as of June 30, 2025, mainly due to partial repayment of bank borrowings[123]. - The gearing ratio improved to 21.1% as of June 30, 2025, down from 43.3% as of December 31, 2024[124]. Corporate Governance and Shareholder Information - The Company adopted a Share Option Scheme for a period of 10 years starting from the Listing Date, aimed at attracting and retaining quality personnel and aligning their interests with shareholders[130][134]. - The roles of the chairman and CEO are both performed by Mr. Wang, which the Board believes enhances responsiveness and effectiveness in business strategy formulation[155]. - The company will continue to review and monitor its corporate governance practices to ensure compliance with the Corporate Governance Code[156]. - As of June 30, 2025, Mr. Wang holds 106,855,884 shares, representing approximately 27.66% of the company's issued share capital[192]. - The total number of ordinary shares issued by the company as of June 30, 2025, is 386,267,244[193]. - The company does not recommend the payment of any interim dividend for the six months ended June 30, 2025[161].

Contents目錄 | Corporate Information 公司資料 | 3 | | --- | --- | | Management Discussion and Outlook 管理層討論及展望 | 5 | | Condensed Consolidated Statement of Profit or Loss 簡明綜合損益表 | 17 | | Condensed Consolidated Statement of Other Comprehensive Income | 19 | | 簡明綜合其他全面收益表 | | | Condensed Consolidated Statement of Financial Position 簡明綜合財務狀況表 | 20 | | Condensed Consolidated Statement of Changes in Equity 簡明綜合權益變動表 | 22 | | Condensed Consolidated Statement of Cash Flows 簡明綜合現金流量表 | 24 | | Notes to the Condensed Conso ...

| 2 | 公司資料 | | --- | --- | | 4 | 管理層討論與分析 | | 16 | 企業管治及其他資料 | | 24 | 簡明綜合財務報表審閱報告 | | 25 | 簡明綜合損益及其他全面收益表 | | 26 | 簡明綜合財務狀況表 | | 28 | 簡明綜合權益變動表 | | 29 | 簡明綜合現金流量表 | | 31 | 簡明綜合財務報表附註 | | 62 | 釋義 | 公司資料 董事會 深圳市天圖投資管理股份有限公司 TIAN TU CAPITAL CO., LTD. （於中華人民共和國註冊成立的股份有限公司） 股份代號 : 1973 2025 中 期 報 告 目錄 刁揚先生 （主席，自2025年5月23日起生效） 王永華先生 王世林先生 （辭任主席，自2025年5月23日起生效） 執行董事 王永華先生 （董事長） 馮衛東先生 鄒雲麗女士 李小毅先生 （於2025年5月23日辭任） 非執行董事 王仕生先生 （於2025年5月23日獲委任） 黎瀾先生 姚嘉雯女士 獨立非執行董事 王世林先生 刁揚先生 蔡洌先生 審計委員會 蔡洌先生 （主席） 姚嘉雯女士 刁揚先生 薪酬委員會 提名委員會 ...

Financial Performance - For the six months ended June 30, 2025, the company reported revenue of RMB 12,935,000, a significant decrease of 91.8% compared to RMB 157,288,000 for the same period in 2024[9]. - The gross profit for the same period was RMB 3,655,000, down from RMB 12,184,000, indicating a decline in profitability[9]. - The company recorded a net loss of RMB 3,564,000 for the six months ended June 30, 2025, compared to a net loss of RMB 16,353,000 in the prior year, showing an improvement in loss[10]. - Total revenue for the six months ended June 30, 2025, was RMB 12,935,000, a decrease of 18.5% compared to RMB 15,857,000 for the same period in 2024[22]. - Net loss for the six months ended June 30, 2025, was RMB 3,564,000, compared to a net loss of RMB 16,353,000 for the same period in 2024, indicating an improvement[22]. - The company reported a total comprehensive loss of RMB 1,805,000 for the six months ended June 30, 2025, compared to a total comprehensive loss of RMB 12,842,000 for the same period in 2024[11]. - The company reported a total comprehensive loss attributable to owners of approximately RMB 1.8 million for the six months ended June 30, 2025, down from RMB 12.8 million for the same period in 2024[56]. Assets and Liabilities - Total assets as of June 30, 2025, were RMB 1,034,999,000, slightly up from RMB 1,015,981,000 at the end of 2024[8]. - The company's total equity decreased to RMB 544,038,000 from RMB 545,843,000 at the end of 2024, reflecting a marginal decline[7]. - The company’s financial liabilities increased to RMB 490,961,000 from RMB 470,138,000, indicating a rise in debt levels[8]. - As of June 30, 2025, the total borrowings of the group amounted to approximately RMB 374.3 million, an increase from RMB 267.1 million as of December 31, 2024[76]. - The debt-to-equity ratio as of June 30, 2025, was approximately 40.8%, up from 32.9% as of December 31, 2024[77]. - The current ratio decreased to approximately 0.87 times as of June 30, 2025, compared to 1.07 times as of December 31, 2024[77]. Cash Flow - The net cash used in operating activities for the six months ended June 30, 2025, is RMB 24,083,000, compared to RMB 25,013,000 for the same period in 2024, indicating a slight improvement[12]. - The net cash used in investing activities for the six months ended June 30, 2025, is RMB 92,611,000, an increase from RMB 79,774,000 in 2024[12]. - The net cash generated from financing activities for the six months ended June 30, 2025, is RMB 106,614,000, significantly higher than RMB 32,644,000 in the previous year[12]. - The company reported a cash and cash equivalents balance of RMB 69,912,000 as of June 30, 2025, a decrease of 12.9% from RMB 80,001,000 as of December 31, 2024[33]. - The group's cash and bank balances were approximately RMB 72.4 million as of June 30, 2025, down from RMB 80.0 million as of December 31, 2024[76]. Operational Highlights - The company’s operations are primarily focused on iron ore processing and the sale of iron concentrates and other minerals in China[13]. - The company processed 103,000 tons of Brazilian coarse powder in the first half of 2025, continuing its processing business[57]. - The sales revenue from coal and coal products trade reached RMB 6.171 million in the first half of 2025, leveraging logistics advantages[57]. - The company aims to increase coal and coal product trading volume by leveraging logistics advantages and existing customer relationships[73]. - The company intends to enhance production capacity at the Zhuge Shangyu processing plant in the second half of 2025, striving for better output compared to the first half[74]. Expenses and Costs - The company’s administrative expenses rose to RMB 29,811,000 from RMB 28,489,000, indicating increased operational costs[9]. - Distribution costs and administrative expenses decreased by approximately RMB 1.8 million or 5.7% to about RMB 29.8 million for the six months ended June 30, 2025[70]. - Employee benefits expenses for the six months ended June 30, 2025, were approximately RMB 7.4 million, compared to RMB 6.8 million for the same period in 2024[81]. - The total sales cost for the six months ended June 30, 2025, decreased by approximately 93.6% to about RMB 9.3 million, down from approximately RMB 145.1 million in the previous year[67]. Investments and Future Plans - The investment in the Zhugeshangyu mining and selection plant construction is approximately RMB 1.5 billion, focusing on mining, production line construction, and automation[57]. - The company plans to invest approximately RMB 1.5 billion in the construction of the Zhuge Shangyu mine and processing plant, focusing on mining operations and production line construction[73]. - The company is actively pursuing low-carbon and environmentally friendly projects, with ongoing ecological enhancement works expected to be completed by the end of the year[58]. - The group plans to focus on low-carbon and sustainable growth projects in the second half of the year[78]. Governance and Compliance - The company has adopted the corporate governance code as its own governance code and believes it has complied with all relevant provisions during the six-month period ending June 30, 2025[98]. - The audit committee, consisting of four independent non-executive directors, reviewed the unaudited interim consolidated results for the six months ending June 30, 2025, ensuring compliance with applicable accounting standards and regulations[99].

Financial Performance - The company reported revenue of RMB 1,269,595,000 for the six months ended June 30, 2025, a decrease of 6.2% compared to RMB 1,353,470,000 in the same period of 2024[10]. - Gross profit for the period was RMB 279,594,000, down 13.9% from RMB 324,692,000 year-on-year[10]. - Net profit for the period decreased by 70.0% to RMB 38,326,000, compared to RMB 127,566,000 in the previous year[10]. - Adjusted net profit (non-GAAP) was RMB 35,628,000, a decline of 72.1% from RMB 127,790,000 in the same period last year[11]. - The revenue from solution services provided to hospitals was RMB 108,899,000, a decrease of 7.3% compared to RMB 117,462,000 for the six months ending June 30, 2024, primarily due to reduced market demand[16]. - The group's total revenue for the six months ended June 30, 2025, was RMB 1,181,820,000, a decrease of 6.1% compared to RMB 1,258,212,000 for the same period in 2024[46]. - The net profit for the period was RMB 38,326,000, down RMB 89,240,000 or 70.0% year-on-year[26]. - Adjusted net profit decreased to RMB 35,628,000, a decline of RMB 92,162,000 or 72.1% compared to the previous year[26]. - The group's profit for the period was RMB 38,326,000, a decrease of 70.0% from RMB 127,566,000 for the six months ended June 30, 2024, attributed to reduced revenue, lower gross margin, increased administrative expenses, and higher selling and distribution expenses[62]. Market and Operational Insights - The company installed approximately 6,605 Sysmex coagulation analyzers in hospitals and medical institutions across China as of June 30, 2025[14]. - The company has been the exclusive distributor of Sysmex coagulation products in China for 27 years, strengthening its market position[15]. - The company continues to enhance its collaboration with Sysmex to adapt to the dynamic demands of the Chinese medical device market[15]. - The company aims to provide a competitive and diverse product portfolio to stabilize market share and profitability[13]. - The Chinese IVD market is expected to reach RMB 278.7 billion by 2027, with a compound annual growth rate (CAGR) of 15.7% from 2021 to 2027[19]. - The company plans to expand its product portfolio and distribution network to capture high growth potential in the IVD market, including establishing relationships with well-known IVD manufacturers[22]. Financial Position and Cash Flow - Total assets increased by 11.5% to RMB 6,159,137,000 from RMB 5,523,884,000[32]. - Cash and cash equivalents decreased significantly by 76.1% to RMB 424,849,000 from RMB 1,774,358,000[32]. - The group's cash and cash equivalents as of June 30, 2025, were RMB 424,849,000, down from RMB 1,774,358,000 as of December 31, 2024[64]. - The net current assets decreased by RMB 247,884,000 or 11.4%, from RMB 2,169,969,000 as of December 31, 2024, to RMB 1,922,085,000 as of June 30, 2025[66]. - The total bank borrowings amounted to RMB 1,655,064,000, all at fixed interest rates, due for repayment by June 30, 2026[73]. - The financing activities generated a net cash flow of RMB 617,723,000, an increase from RMB 413,594,000 in 2024, primarily due to new bank borrowings[94]. - The net cash flow from operating activities was RMB (1,869,376) thousand, a significant decrease compared to RMB 3,737 thousand for the same period in 2024[93]. - The net cash flow used in investing activities was RMB (91,360) thousand, compared to RMB (55,796) thousand in the previous year, indicating increased investment outflows[93]. Expenses and Cost Management - Selling and distribution expenses increased by 17.0% to RMB 70,314,000 from RMB 60,090,000 for the six months ended June 30, 2024, mainly due to increased technical service fees paid to a potential partner[57]. - Administrative expenses rose by 23.0% to RMB 93,652,000 from RMB 76,169,000 for the same period in 2024, primarily due to increased labor costs[59]. - Other expenses increased significantly by 1,744.4% to RMB 24,899,000 from RMB 1,350,000 for the six months ended June 30, 2024, mainly due to increased foreign exchange losses[60]. - Financing costs increased by 92.7% to RMB 22,414,000 from RMB 11,629,000 for the same period in 2024, primarily due to an increase in average bank borrowings[61]. Shareholder and Equity Information - The company issued 270,918,016 new shares at a placement price of HKD 0.7 per share, raising approximately RMB 173,142,000, which contributed to an increase in share capital[133]. - The company repurchased and cancelled shares amounting to RMB (8,117) thousand during the period[93]. - The total equity attributable to the company's owners was RMB 3,466,972,000 as of June 30, 2025, down from RMB 3,714,618,000 as of December 31, 2024[65]. - The company has not declared any interim dividends for the reporting period, with no dividends declared for the six months ending June 30, 2024[185]. Strategic Initiatives and Future Plans - The company has established a global strategic cooperation framework with HashKey Group to optimize trading costs and strengthen asset management mechanisms in the digital asset financial services sector[24]. - The company plans to adopt a regular investment strategy to continuously increase its Ethereum holdings[25]. - The board proposed to seek shareholder approval for potential cryptocurrency purchases not exceeding HKD 3 billion over the next 36 months[147]. - The company is pursuing a dual primary listing on the NASDAQ through the issuance of American Depositary Shares[187]. - The company has entered into a strategic cooperation framework agreement with HashKey Group to enhance digital asset services and has purchased 5,190 ETH at USD 3,661 each[190]. Employee and Management Compensation - The total employee compensation expenses for the reporting period were RMB 75,403,000, an increase from RMB 66,402,000 for the six months ended June 30, 2024[80]. - Total compensation for key management personnel increased to RMB 10,248,000 for the six months ended June 30, 2025, compared to RMB 8,135,000 for the same period in 2024, reflecting a growth of about 26%[138]. - The company recorded a significant increase in short-term employee benefits to RMB 9,531,000 for the six months ended June 30, 2025, compared to RMB 7,555,000 for the same period in 2024, marking an increase of about 25.9%[138]. Stock Options and Incentive Plans - The stock option plan aims to attract and retain talent, providing additional incentives to eligible participants[158]. - The number of stock options granted to any eligible participant within a twelve-month period is limited to 1% of the total issued shares[160]. - The company has adopted a new share incentive plan effective after the reporting period, with details provided in a circular dated June 6, 2025[177]. - The maximum number of shares that can be granted under the share incentive plan is limited to 10% of the company's issued share capital, with individual grants not exceeding 1%[170]. - The company has not granted any shares under the share incentive plan during the reporting period[177].

Financial Performance - The Group recorded revenue of approximately HK$124.1 million for the six months ended 30 June 2025, a decrease of 1.0% compared to HK$125.3 million for the same period in 2024[10]. - Overall gross profit increased to approximately HK$28.2 million, representing a 13.7% increase from approximately HK$24.8 million for the six months ended 30 June 2024[10]. - The Group reported a consolidated net loss of approximately HK$0.7 million for the Period, compared to a net profit of approximately HK$5.7 million for the six months ended 30 June 2024[11]. - Revenue for the six months ended June 30, 2025, was HK$124,144,000, a decrease of 0.9% from HK$125,321,000 in 2024[53]. - Gross profit increased to HK$28,164,000, representing a 13.4% increase from HK$24,785,000 in the previous year[53]. - Profit before taxation decreased to HK$2,233,000, down 73.8% from HK$8,507,000 in 2024[53]. - The Group reported a segment loss of HK$1,040,000 from construction and ancillary services, while the consumer goods business generated a segment profit of HK$7,902,000, leading to a total segment profit of HK$6,862,000[79]. - The Group incurred a loss of HK$706,000 for the period after taxation, compared to a profit of HK$5,711,000 for the same period in 2024[81]. Revenue Breakdown - Revenue from the consumer goods business contributed approximately HK$95.0 million to the Group for the six months ended 30 June 2025[11]. - The construction and ancillary services segment generated revenue of approximately HK$29.1 million, accounting for 23.5% of total revenue, down from HK$43.2 million (34.5%) in the previous year[25]. - The consumer goods business accounted for 76.5% of total revenue, up from 65.5% in the previous year[25]. - Revenue from construction and ancillary services decreased by 32.6% to approximately HK$29.1 million compared to HK$43.2 million for the six months ended 30 June 2024[26][27]. - Revenue from consumer goods business accounted for approximately 76.5% of total revenue, amounting to approximately HK$95.0 million, up from approximately HK$82.1 million for the six months ended 30 June 2024[28][33]. - Revenue from Hong Kong increased to HK$29,116,000 in 2025, up 45.6% from HK$19,975,000 in 2024[87]. - Revenue from the PRC rose to HK$95,028,000, an increase of 15.6% compared to HK$82,146,000 in 2024[87]. Economic Outlook and Strategy - The Group anticipates a recovery in the economic environment in Hong Kong, Macau, and the PRC, which is expected to enhance business performance in 2025[12]. - The Group plans to commence more construction projects in Hong Kong and Macau to maintain a stable revenue stream in 2025[12]. - The Group aims to maximize shareholder value by exploring new business opportunities in consumer goods and other sectors[13]. - The management remains committed to a pragmatic approach in executing business strategies to broaden the revenue and profit base[13]. - The Group anticipates a recovery in the economic environment in 2025, which is expected to enhance business performance and lead to more construction projects in Hong Kong and Macau[31][36]. - The Group will continue to explore new business opportunities to broaden its revenue and profit base, particularly in the consumer goods sector[32][36]. Financial Position - The Group had total cash and bank balances of approximately HK$80.7 million as of 30 June 2025, up from approximately HK$62.2 million as of 31 December 2024[41][48]. - Net current assets increased to approximately HK$468.9 million as of 30 June 2025, compared to approximately HK$328.1 million as of 31 December 2024[42][48]. - The current ratio improved to approximately 4.6 times as of 30 June 2025, compared to approximately 3.8 times as of 31 December 2024[42][48]. - The gearing ratio decreased to approximately 13.7% as of 30 June 2025, down from approximately 21.3% as of 31 December 2024[43][48]. - Total equity increased to HK$549,086,000 from HK$351,604,000, reflecting a solid capital structure[57]. - Cash flows from operating activities resulted in a net cash used of HK$112,726,000 for the six months ended June 30, 2025, compared to HK$29,520,000 for the same period in 2024[63]. - The net cash generated from financing activities was HK$184,845,000 for the six months ended June 30, 2025, compared to HK$24,021,000 in the same period of 2024[63]. - The Group's inventory of consumer goods was HK$199.5 million as of June 30, 2025, significantly up from HK$89.3 million as of December 31, 2024[116]. Shareholder Information - Basic and diluted loss per share attributable to owners of the company was HK$0.04, down from earnings of HK$0.37 in 2024[53]. - The company does not recommend the payment of an interim dividend for the six months ended June 30, 2025, consistent with the previous year[102]. - As of June 30, 2025, the company had 1,866,240,000 issued and fully paid ordinary shares, an increase from 1,555,200,000 shares as of June 30, 2024, representing a growth of approximately 20%[134]. - The weighted average number of ordinary shares in issue increased to 1,866,240,000 in 2025 from 1,555,200,000 in 2024[105]. - The Group does not recommend the payment of an interim dividend for the six months ended June 30, 2025, consistent with the previous year where no dividend was declared[140]. Management and Governance - The Company has maintained a public float of not less than 25% of the issued shares during the six months ended 30 June 2025[183]. - The Audit Committee reviewed the accounting principles and unaudited condensed consolidated financial statements for the six months ended 30 June 2025[178]. - There were no changes in the information regarding directors for the six months ended 30 June 2025[173]. - The Company did not purchase, sell, or redeem any of its listed securities for the six months ended 30 June 2025[172]. - No arrangements were made for Directors to acquire benefits through the acquisition of shares or debentures during the six months ended 30 June 2025[165].